...
首页> 外文期刊>The Biochemical Journal >Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1
【24h】

Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1

机译:核糖体S6激酶2的突变分析表明其激酶活性与核糖体S6激酶1的调节不同

获取原文
获取原文并翻译 | 示例
           

摘要

Ribosomal S6 kinase 2 (S6K2) is a serine/threonine kinase identified as a homologue of p70 ribosomal S6 kinase 1 (S6K1). S6K1 and S6K2 show different cellular localization as well as divergent amino acid sequences in non-catalytic domains, suggesting that their cellular functions and/or regulation may not be identical. Many of the serine/threonine residues that become phosphorylated and contribute to S6K1 activation are conserved in S6K2. In this study we carry out mutational analyses of these serine/threonine residues on S6K2 in order to elucidate the mechanism of S6K2 regulation. We find that Thr-228 and Ser-370 are crucial for S6K2 activity, and the three proline-directed serines in the autoinhibitory domain, Ser-410, Ser-417 and Ser-423, play a role in S6K2 activity regulation in a mitogen-activated protein kinase/extracellular-signal-regulated kinase kinase (MEK)-dependent manner. However, unlike S6K1, changing Thr-388 to glutamic acid in S6K2 renders the kinase fully active. This activity was resistant to the effects of rapamycin or wortmannin, indicating that mammalian target of rapamycin (mTOR) and phosphoinositide 3-kinase (PI3K) regulate S6K2 activity via Thr-388. MEK-dependent phosphorylation of the autoinhibitory serines in S6K2 occurs prior to Thr-388 activation. Combining T388E and T228A mutations inhibited S6K2 activation, and a kinase-inactive phosphoinositide-dependent protein kinase (PDK1) diminished T388E activity, suggesting that the role of Thr-388 is to allow further phosphorylation of Thr-228 by PDK1. Thr-388 fails to become phosphorylated in Ser-370 mutants, suggesting that the role of Ser-370 phosphorylation may be to allow Thr-388 phosphorylation. Finally, using the rapamycin-resistant T388E mutant, we provide evidence that S6K2 can phosphorylate S6 in vivo. [References: 34]
机译:核糖体S6激酶2(S6K2)是一种丝氨酸/苏氨酸激酶,被鉴定为p70核糖体S6激酶1(S6K1)的同源物。 S6K1和S6K2在非催化域中显示不同的细胞定位以及不同的氨基酸序列,表明它们的细胞功能和/或调控可能不相同。在S6K2中保守了许多被磷酸化并有助于S6K1活化的丝氨酸/苏氨酸残基。在这项研究中,我们对S6K2上的这些丝氨酸/苏氨酸残基进行突变分析,以阐明S6K2调控的机制。我们发现Thr-228和Ser-370对S6K2活性至关重要,并且自抑制域中的三个脯氨酸定向丝氨酸Ser-410,Ser-417和Ser-423在丝裂原中的S6K2活性调节中发挥作用激活的蛋白激酶/细胞外信号调节激酶激酶(MEK)依赖方式。但是,与S6K1不同,在S6K2中将Thr-388更改为谷氨酸使该激酶具有完全活性。该活性对雷帕霉素或渥曼青霉素的作用具有抗性,表明雷帕霉素(mTOR)和磷酸肌醇3-激酶(PI3K)的哺乳动物靶标通过Thr-388调节S6K2活性。在Thr-388激活之前,S6K2中自抑制丝氨酸的MEK依赖性磷酸化发生。结合T388E和T228A突变可抑制S6K2活化,激酶失活的磷酸肌醇依赖性蛋白激酶(PDK1)会降低T388E的活性,这表明Thr-388的作用是允许PDK1进一步使Thr-228磷酸化。 Thr-388无法在Ser-370突变体中被磷酸化,表明Ser-370磷酸化的作用可能是允许Thr-388磷酸化。最后,使用耐雷帕霉素的T388E突变体,我们提供了S6K2可以在体内磷酸化S6的证据。 [参考:34]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号